Is Oxytocin Proper for Cancer Adjuvant Therapy? †
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Author Contributions
Acknowledgments
Conflicts of Interest
References
- Maris, J.M.; Hogarty, M.D.; Bagatell, R. Neuroblastoma. Lancet 2007, 369, 2106–2120. [Google Scholar] [CrossRef]
- Sanie-Jahromi, F.; Saadat, M. Different profiles of the mRNA levels of DNA repair genes in MCF-7 and SH-SY5Y cells after treatment with combination of cisplatin, 50-Hz electromagnetic field and bleomycin. Biomed. Pharmacother. 2017, 94, 564–568. [Google Scholar] [CrossRef] [PubMed]
- Tu, Y.; Cheng, S.; Zhang, S.; Sun, H.; Xu, Z. Vincristine induces cell cycle arrest and apoptosis in SH-SY5Y human neuroblastoma cells. Int. J. Mol. Med. 2013, 31, 113–119. [Google Scholar] [CrossRef] [PubMed]
- Bakos, J.; Strbak, V.; Ratulovska, N.; Bacova, Z. Effect of oxytocin on neuroblastoma cell viability and growth. Cell. Mol. Neurobiol. 2012, 32, 891–896. [Google Scholar] [CrossRef] [PubMed]
- Taghizadehghalehjoughi, A.; Hacimuftuoglu, A.; Cetin, M.; Ugur, A.B.; Galateanu, B.; Mezhuev, Y.; Okkay, U.; Taspinar, N.; Taspinar, M.; Uyanik, A.; et al. Effect of metformin/irinotecan-loaded poly-lactic-co-glycolic acid nanoparticles on glioblastoma: In vitro and in vivo studies. Nanomedicine 2018, 13, 1595–1606. [Google Scholar] [CrossRef] [PubMed]
- Erel, O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin. Biochem. 2004, 37, 277–285. [Google Scholar] [CrossRef] [PubMed]
- Erel, O. A new automated colorimetric method for measuring total oxidant status. Clin. Biochem. 2005, 38, 1103–1111. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Taghizadehghalehjoughi, A.; Cicek, B.; Hacimuftuoglu, A.; Gul, M. Is Oxytocin Proper for Cancer Adjuvant Therapy? Proceedings 2018, 2, 1582. https://doi.org/10.3390/proceedings2251582
Taghizadehghalehjoughi A, Cicek B, Hacimuftuoglu A, Gul M. Is Oxytocin Proper for Cancer Adjuvant Therapy? Proceedings. 2018; 2(25):1582. https://doi.org/10.3390/proceedings2251582
Chicago/Turabian StyleTaghizadehghalehjoughi, Ali, Betul Cicek, Ahmet Hacimuftuoglu, and Mustaf Gul. 2018. "Is Oxytocin Proper for Cancer Adjuvant Therapy?" Proceedings 2, no. 25: 1582. https://doi.org/10.3390/proceedings2251582
APA StyleTaghizadehghalehjoughi, A., Cicek, B., Hacimuftuoglu, A., & Gul, M. (2018). Is Oxytocin Proper for Cancer Adjuvant Therapy? Proceedings, 2(25), 1582. https://doi.org/10.3390/proceedings2251582